Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against ArriVent BioPharma, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
About This Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of ArriVent BioPharma, Inc. (NASDAQ: AVBP).
On October 6, 2026, ArriVent BioPharma, Inc. announced that its global Phase 3 FURVENT trial evaluating firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer failed to meet its primary endpoint of progression-free survival. Previously, the Company had stated in a November 10, 2025 filing that no interim analysis had been conducted or was planned, and subsequently filed a May 11, 2026 prospectus supporting an at-the-market offering of up to $250 million while describing its ongoing Phase 3 trial. The investigation concerns whether ArriVent adequately disclosed information regarding the trial’s progress and the timing of any negative efficacy data. Following the October 6 announcement, ArriVent’s stock price declined approximately 50%–63% during the trading session, reaching a 52-week low of approximately $12.09.
What We Are Investigating
- Whether ArriVent BioPharma, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether ArriVent BioPharma, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Investors Should Do
AVBP — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”